Royal Bank of Canada’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-5,562
| Closed | -$214K | – | 7915 |
|
|
2023
Q2 | $214K | Buy |
5,562
+702
| +14% | +$18K | ﹤0.01% | 4690 |
|
|
2023
Q1 | $113K | Sell |
4,860
-3,176
| -40% | -$75.7K | ﹤0.01% | 5089 |
|
|
2022
Q4 | $210K | Buy |
8,036
+6,816
| +559% | +$151K | ﹤0.01% | 4840 |
|
|
2022
Q3 | $24K | Buy |
1,220
+973
| +394% | +$19.5K | ﹤0.01% | 6076 |
|
|
2022
Q2 | $4K | Sell |
247
-2,231
| -90% | -$35K | ﹤0.01% | 6786 |
|
|
2022
Q1 | $41K | Sell |
2,478
-4,996
| -67% | -$67.9K | ﹤0.01% | 6228 |
|
|
2021
Q4 | $122K | Buy |
7,474
+4,410
| +144% | +$62.8K | ﹤0.01% | 5785 |
|
|
2021
Q3 | $39K | Buy |
3,064
+882
| +40% | +$11.6K | ﹤0.01% | 6309 |
|
|
2021
Q2 | $30K | Buy |
2,182
+1,439
| +194% | +$23K | ﹤0.01% | 6351 |
|
|
2021
Q1 | $11K | Buy |
+743
| New | +$12.1K | ﹤0.01% | 6786 |
|
|
2020
Q3 | – | Sell |
-1,089
| Closed | -$13K | – | 7058 |
|
|
2020
Q2 | $13K | Sell |
1,089
-453
| -29% | -$6.25K | ﹤0.01% | 5752 |
|
|
2020
Q1 | $21K | Buy |
1,542
+1,502
| +3,755% | +$17.8K | ﹤0.01% | 5530 |
|
|
2019
Q4 | $0 | Sell |
40
-97
| -71% | -$527 | ﹤0.01% | 7231 |
|
|
2019
Q3 | $1K | Sell |
137
-18
| -12% | -$119 | ﹤0.01% | 6557 |
|
|
2019
Q2 | $1K | Hold |
155
| – | – | ﹤0.01% | 6765 |
|
|
2019
Q1 | $3K | Sell |
155
-3
| -2% | -$52 | ﹤0.01% | 6466 |
|
|
2018
Q4 | $2K | Sell |
158
-647
| -80% | -$12.9K | ﹤0.01% | 6494 |
|
|
2018
Q3 | $30K | Buy |
805
+36
| +5% | +$1.16K | ﹤0.01% | 5482 |
|
|
2018
Q2 | $27K | Buy |
769
+92
| +14% | +$3.53K | ﹤0.01% | 5423 |
|
|
2018
Q1 | $31K | Sell |
677
-241
| -26% | -$8.82K | ﹤0.01% | 5278 |
|
|
2017
Q4 | $34K | Sell |
918
-613
| -40% | -$26.8K | ﹤0.01% | 5356 |
|
|
2017
Q3 | $82K | Buy |
1,531
+1,156
| +308% | +$68.7K | ﹤0.01% | 5144 |
|
|
2017
Q2 | $22K | Sell |
375
-158
| -30% | -$7.93K | ﹤0.01% | 5503 |
|
|
2017
Q1 | $29K | Buy |
533
+90
| +20% | +$5.08K | ﹤0.01% | 5437 |
|
|
2016
Q4 | $24K | Buy |
443
+268
| +153% | +$16.2K | ﹤0.01% | 5681 |
|
|
2016
Q3 | $11K | Sell |
175
-49
| -22% | -$3.46K | ﹤0.01% | 5760 |
|
|
2016
Q2 | $12K | Sell |
224
-37
| -14% | -$2.25K | ﹤0.01% | 5694 |
|
|
2016
Q1 | $17K | Buy |
261
+152
| +139% | +$12.3K | ﹤0.01% | 5559 |
|
|
2015
Q4 | $15K | Buy |
109
+34
| +45% | +$4.62K | ﹤0.01% | 5839 |
|
|
2015
Q3 | $7K | Sell |
75
-126
| -63% | -$15K | ﹤0.01% | 6060 |
|
|
2015
Q2 | $31K | Buy |
+201
| New | +$33.2K | ﹤0.01% | 5475 |
|
Royal Bank of Canada's KDNY Position: Q3 2023 in Review
Royal Bank of Canada sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 5,562 shares — an estimated $214K sold.
Royal Bank of Canada first reported a position in KDNY in Q2 2015 and held it in 31 quarters. The position peaked at $214K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Royal Bank of Canada reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Royal Bank of Canada sold 5,562 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $214K.
- Royal Bank of Canada first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 31 quarters.
- Royal Bank of Canada's Chinook Therapeutics, Inc. Common Stock position peaked at $214K in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Royal Bank of Canada's 13F filing for Q3 2023, filed 14 Nov 2023.